fuzzyjr

The just issued financial statements are for Zenith's 3rd quarter ended 1/31/24.

Some items of interest:

Zenith's cash burn for the 9 months ended 1/31 was 7.7mil which included 3.5mil net cash payments to RVX. 

RVX owed Zen 4.4mil at 1/31 and was advanced another .6 mil since 1/31/24 bringing the total to 5.0 mil.

Zen is currently funding RVX (See not 5, p9 of the financials).

Zen's cash bal at 1/31 was 1.1mil 

Zenith borrrowed 5mil from a private investor in 11/23. The convertible note has has an interest rate of 18% and is guauranteed by the CEO and Chm up to 2.5mil.

Zen anticipates an interim trial readout in late 2024/early 2025 on its ph2b mCRPC study and a late 2024 readout on its solid tumor collaboration with Merck (p12 of MD&A)

Time for BP to step in 

Chicagoest